Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

Management of a Patient with a Positive M-Spike

Initial Diagnostic Evaluation

  • The National Comprehensive Cancer Network recommends a complete blood count with differential to assess for anemia, which is a common indicator of disease progression 2
  • The National Comprehensive Cancer Network suggests a comprehensive metabolic panel including serum creatinine, calcium, and albumin to evaluate for end-organ damage 2
  • Quantitative immunoglobulin levels (IgG, IgA, IgM) are used to determine the type and level of abnormal antibodies, as recommended by the National Comprehensive Cancer Network 2
  • Serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) are used to identify and quantify the M-protein, as recommended by the National Comprehensive Cancer Network 2
  • The National Comprehensive Cancer Network recommends a serum free light chain (FLC) assay to determine kappa/lambda ratio and quantify involved light chains 2
  • A 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE) is recommended by the National Comprehensive Cancer Network 2
  • Bone marrow aspiration and biopsy with immunohistochemistry are used to determine plasma cell percentage and clonality, as recommended by the International Myeloma Society 1
  • Cytogenetic studies including FISH for prognostic markers (17p13, t(4;14), t(14;16)) are recommended by the International Myeloma Society 4
  • Imaging studies: skeletal survey or more sensitive imaging like whole-body low-dose CT, MRI, or PET/CT are recommended by the National Comprehensive Cancer Network 5
  • Serum β2-microglobulin and lactate dehydrogenase are used for prognostic assessment, as recommended by the National Comprehensive Cancer Network 2

Diagnostic Criteria and Classification

  • The International Myeloma Society defines MGUS criteria as serum M-protein <3 g/dL, clonal bone marrow plasma cells <10%, absence of end-organ damage, and absence of amyloidosis or other related disorders 1, 4
  • The International Myeloma Society defines smoldering multiple myeloma criteria as serum M-protein ≥3 g/dL and/or clonal bone marrow plasma cells 10-60%, absence of end-organ damage or amyloidosis 2, 6
  • The International Myeloma Society defines multiple myeloma criteria as clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma, evidence of end-organ damage or myeloma-defining events 2, 8

Risk Stratification

  • The International Myeloma Society recommends MGUS risk stratification as low risk: M-protein <1.5 g/dL, IgG type, normal FLC ratio, intermediate risk: one risk factor present, high risk: two or more risk factors present (M-protein ≥1.5 g/dL, non-IgG type, abnormal FLC ratio) 1
  • The International Myeloma Society recommends SMM risk stratification as low risk: M-protein <3 g/dL, <10% bone marrow plasma cells, intermediate risk: M-protein ≥3 g/dL or ≥10% bone marrow plasma cells, high risk: both M-protein ≥3 g/dL and ≥10% bone marrow plasma cells, or other high-risk features 6, 8

Management Approach

  • The National Comprehensive Cancer Network recommends observation as the standard of care for smoldering multiple myeloma, with clinical follow-up every 3 months for the first year to establish pattern of evolution 7
  • The National Comprehensive Cancer Network recommends initiation of appropriate treatment for multiple myeloma based on patient factors and disease characteristics, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and/or stem cell transplantation in eligible patients 2, 8, 9

Follow-up Recommendations

  • The International Myeloma Society recommends MGUS follow-up as low-risk: SPEP, CBC, calcium, and creatinine every 2-3 years, intermediate/high-risk: SPEP, CBC, calcium, and creatinine annually 1, 2
  • The International Myeloma Society recommends SMM follow-up as SPEP, CBC, calcium, and creatinine every 3 months for the first year, if stable, extend to every 4-6 months, more frequent monitoring for high-risk features 1, 2

Pitfalls to Avoid

  • The National Comprehensive Cancer Network warns against failing to distinguish between MGUS, SMM, and MM, which have different management approaches 1, 2
  • The National Comprehensive Cancer Network advises against initiating treatment for SMM outside of clinical trials, as observation remains the standard of care 6, 8
  • The International Myeloma Society recommends assessing for bone disease with appropriate imaging techniques, such as skeletal survey or more sensitive imaging like whole-body low-dose CT, MRI, or PET/CT 2, 5